Ucb Pharma, S.a.

Fred Hutchinson Cancer Center

Battelle Memorial Institute

The Ohio State University

Institute for Systems Biology

Richard Evan Gelinas

Ralph Adams

Andrew George Popplewell

Yi Lin Zhang

Mitra Choudhury Singhal

Steven Henikoff

Kai Hua Wang

David J Galas

Shile Zhang

Clay Braden Marsh

Melissa Garnet Piper

Kai Wang

The invention relates to antibody molecules having specificity for antigenic determinants of IL-6, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

Methods for treating IL-6 mediated diseases with antibody molecules specific for IL-6

Methods for making antibody molecules having specificity for human IL-6

Methods, compositions, and devices are disclosed which use microRNA to detect, predict, treat, and monitor physiological conditions such as disease or injury. microRNA are isolated and their differential expression is measured to provide diagnostic information. This information may then be utilized for evaluation and/or treatment purposes.

Methods, compositions, and devices utilizing MicroRNA to determine physiological conditions

DNA encoding antibody molecules having specificity for human IL-6

Antibody molecules having specificity for human IL-6

A process is provided for producing an ordered series of cloned, circular, DNA molecules containing shortened target DNA segments derived from a long target DNA segment, which are suitable for use in determining the nucleotide sequence of the long target DNA segment, or for targeting specific regions within the target DNA segment. The process includes producing, by molecular cloning, a plurality of double-stranded recombinant DNA molecules each containing: (i) vector DNA; (ii) a sequencing primer binding site; and, (iii) a DNA region having unique endonuclease sites and a long target DNA segment. The sequencing primer binding site is spaced from the long target DNA segment by at least a portion of said DNA region having the unique endonuclease sites. The plurality of double-stranded circular recombinant DNA molecules are cleared using two restriction endonucleases. The cleavage occurs in the portion of the DNA having unique endonuclease sites lying between the long target DNA segment and the sequencing primer binding site. The cleavage and, if necessary, subsequent processing steps, produces double-stranded linear DNA molecules having an end containing a long target DNA segment that is susceptible to exonuclease digestion and a sequencing primer binding site end that is not susceptible to exonuclease digestion. Next, the target DNA segment end is subjected to exonuclease digestion. At timed intervals, portions of the exonuclease digested linear double-stranded DNA molecules are removed. Since part of the target DNA segment has been deleted by the exonuclease, the removed linear double-stranded DNA molecules include shortened target DNA segments. Next, the removed linear double-stranded DNA molecules are blunted and then recircularized to reform circular recombinant DNA molecules. The reformed recombinant DNA molecules are cloned to produce a plurality of circular DNA molecules containing shortened target DNA segments that differ in length by the amount of target DNA that was removed by the exonuclease. The reformed circular DNA molecules are suitable for use in DNA sequencing other molecular manipulations of genetic material.

Reagent kit producing shortened target DNA segments usable in sequencing

A process is provided for producing an ordered series of cloned, circular, DNA molecules containing shortened target DNA segments derived from a long target DNA segment, which are suitable for use in determining the nucleotide sequence of the long target DNA segment, or for targeting specific regions within the target DNA segment. The process includes producing, by molecular cloning, a plurality of double-stranded recombinant DNA molecules each containing: (i) vector DNA; (ii) a sequencing primer binding site; and, (iii) a DNA region having unique endonuclease sites and a long target DNA segment. The sequencing primer binding site is spaced from the long target DNA segment by at least a portion of said DNA region having the unique endonuclease sites. The plurality of double-stranded circular recombinant DNA molecules are cleared using two restriction endonucleases. The cleavage occurs in the portion of the DNA having unique endonuclease sites lying between the long target DNA segment and the sequencing primer binding site. The cleavage and, if necessary, subsequent processing steps, produces double-stranded linear DNA molecules having an end containing a long target DNa segment that is susceptible to exonuclease digestion and a sequencing primer binding site end that is not susceptible to exonuclease digestio

Process for producing shortened target DNA fragments usable in

Growing community of inventors

Seattle, WA, United States of America

Richard Evan Gelinas